Clinical Trials on Anti-PD-1 Antibody

Total 285 results

University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody Improve Mixed Chimerism (HLH)

PD-1 Antibody | Mixed Chimerism

China
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib | Anti-PD-1 Antibody | Advanced Pancreatic Cancer

China
West China Hospital
First Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaborators

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr Deficiency

China
Lei Li

Completed

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Chemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery

China
Lei Li

Recruiting

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Chemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound Paclitaxel

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Apatinib | PD-1 Antibody | Transarterial Chemoembolization

China
Anhui Provincial Hospital

Not yet recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

High Titers of Anti-HLA Antibody (MFI ≥5000)

China
China Medical University, China

Not yet recruiting

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
Assistance Publique - Hôpitaux de Paris
Etablissement Français du Sang (Nouvelle Aquitaine)

Recruiting

Obstetrical History and Anti-HLA Antibodies Level (OBS-HLA)

Blood Donors | Anti-HLA Antibody

France
Shanghai Zhongshan Hospital

Active, not recruiting

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer | PD-1 Antibody | Lenvatinib | Gemox

China
Beijing Friendship Hospital

Completed

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 Therapy

China
Nanjing University School of Medicine

Completed

MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis

Vasculitis | Anti-Neutrophil Cytoplasmic Antibody

China
Guohui Li

Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1 | Immune Related Adverse Events

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Medical University of Graz

Terminated

Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines (CoVVacBoost)

Anti-SARS-CoV-2 Antibody Response

Austria
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFR

China
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
Amgen

Completed

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Amgen

Completed

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Japan
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Chronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNα

China
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Chronic Hepatitis b | Anti-PD-1 Antibody

China
Amgen

Completed

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Xuanwu Hospital, Beijing

Unknown

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Non-small Cell Lung Cancer | PD-1 Antibody | Lung Cancer Stage II
The First Hospital of Jilin University

Not yet recruiting

Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

Locally Advanced Rectal Cancer | Anti-PD-1 | Total Neoadjuvant Treatment

China
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Chemotherapy Effect | Lung Cancer Stage IV | PD-1 Antibody | Lung Cancer Squamous Cell

China
Agenus Inc.

Completed

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Advanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1

United States
Lei Li

Unknown

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Chemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 Antibody

China
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin

Not yet recruiting

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (SATELITE)

Granulomatosis With Polyangiitis | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

France
Amgen

Recruiting

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Chemotherapy | Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy

China
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
National Institute of Allergy and Infectious Diseases...

Completed

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

HIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal Antibody

United States
Southeast University, China

Unknown

Immunoregulatory Therapy for 2019-nCoV

2019 nCoV, PD-1
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Chest Hospital

Unknown

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Chemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
Amgen

Completed

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

United States
Mårten Segelmark
Hansa Biopharma AB

Completed

Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES-01)

Anti-Glomerular Basement Membrane Antibody Disease

Austria, Czechia, Denmark, France, Sweden
Sun Yat-sen University

Completed

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

Brain Metastases | NSCLC Stage IV | PD-1 Antibody

China
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Withdrawn

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

United States
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Withdrawn

Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

United States
Shandong New Time Pharmaceutical Co., LTD

Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL

RR DLBCL; PD-1; CD20

Clinical Trials on Anti-PD-1 Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations